
SL BIO completes merger, lists on Nasdaq to advance off-the-shelf cancer cell therapies.
SL BIO Ltd. has finalized its merger with Horizon Space Acquisition II and will begin trading on Nasdaq under the ticker SLBT. The deal, valuing SL BIO at about $5.57 billion and including $7.8 million in PIPE financing, provides capital to develop i...

